VACCELERATE Clinical Studies
Clinical trials serve the purpose of clarifying open questions regarding new vaccines, therapies or medicines. By participating in clinical trials, you can make a major contribution to scientific progress. As a study participant you support the research of diseases and the development of new treatment options and at the same time receive comprehensive medical care.
VACCELERATE is carrying out three COVID-19 vaccine trials. The results will be linked here as soon as they are published.
STUDY 1: EU-COVAT-1 AGED
A Multinational, Phase 2, Randomised, Adaptive Protocol to Evaluate Immunogenicity and Reactogenicity of Different COVID-19 Vaccines Administration in Older Adults (≥75) Already Vaccinated Against SARS-CoV-2
Lead: Oliver Cornely, Institution/Sponsor: UHC, Germany
A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network – PubMed (nih.gov)
STUDY 2: EU-COVAT-2 BOOSTAVAC
An International Multicentre, Phase 2, Randomised, Adaptive Protocol to determine the need for, optimal timing of and immunogenicity of administering a booster mRNA vaccination dose against SARS-CoV-2 in the general population (18+ years) already vaccinated against SARS-CoV-2
Lead: Patrick Mallon, Institution/Sponsor: NUID UCD, Ireland
STUDY 3: EU-COVPT-1 COVACC
A Phase 2, Comparative Randomised Trial to Evaluate the Impact of Reduced COVID‐19 mRNA Vaccination Regimen on Immunological Responses and Reactogenicity in Paediatric Subjects with Prior SARS‐CoV‐2 Immunity
Lead: Patricia Bruijning-Verhagen, Institution/Sponsor: UMCU, Netherlands
EudraCT number: 2021-005043-71